The Medicines Company (MDCO) - Strategic SWOT Analysis Review

Date: July 30, 2014
Pages: 37
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: TA11AFA2CA0EN
Leaflet:

Download PDF Leaflet

The Medicines Company (MDCO) - Strategic SWOT Analysis Review
The Medicines Company (MDCO) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
Highlights

The Medicines Company (TMC) is a pharmaceutical company providing medical solutions for improving health conditions in critical care patients. The product portfolio of the company comprises of four marketed products, namely, Angiomax (bivalirudin), Recothrom Thrombin, topical (Recombinant), Cleviprex; and Argatroban and seven pipeline products which include five late-stage development products such as cangrelor, oritavancin, Fibrocaps, RPX-602 and IONSYS (fentanyl iontophoretic transdermal system), and two early stage development product such as MDCO-216,and ALN-PCS. The company also provides acute care generic pharmaceuticals products.

The Medicines Company Key Recent Developments

Jul 23, 2014 The Medicines Company Reports Second Quarter and First Half 2014 Results
Jun 05, 2014 New antibiotic could provide single-dose option for skin infections
Jun 04, 2014 The Medicines Company Presents Seven Hospital Data Analyses at Leading Health Economics and Outcomes Research Conferences
Apr 23, 2014 The Medicines Company Reports First Quarter 2014 Financial Results
Apr 18, 2014 Pomerantz Law Firm Announces the Filing of a Class Action Against The Medicines Company and Certain Officers

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
SECTION 1 - ABOUT THE COMPANY

The Medicines Company - Key Facts
The Medicines Company - Key Employees
The Medicines Company - Key Employee Biographies
The Medicines Company - Major Products and Services
The Medicines Company - Pharmaceutical Pipeline Products Data
The Medicines Company, Pipeline Products by Therapy Area
The Medicines Company, Pipeline Products by Development Phase
The Medicines Company - History
The Medicines Company - Company Statement
The Medicines Company - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

The Medicines Company - Business Description
The Medicines Company - Corporate Strategy
The Medicines Company - SWOT Analysis
SWOT Analysis - Overview
The Medicines Company - Strengths
Strength - Marketed Product Portfolio
Strength - Focused Research and Development Activities
Strength - Inorganic Growth: Strategic Acquisitions
The Medicines Company - Weaknesses
Weakness - Operational Inefficiency
Weakness - Geographical Concentration: The US
Weakness - Dependence on Third Party Manufacturers
Weakness - Complete Response Letter
The Medicines Company - Opportunities
Opportunity - Qualified Infectious Disease Product Designation
Opportunity - Demographic Trends
Opportunity - Strategic Collaborations and Agreements
The Medicines Company - Threats
Threat - Competitive Landscape
Threat - Government Regulations
Threat - Uncertain R&D Outcomes
The Medicines Company - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
The Medicines Company, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Jul 23, 2014: The Medicines Company Reports Second Quarter and First Half 2014 Results
Jun 05, 2014: New antibiotic could provide single-dose option for skin infections
Jun 04, 2014: The Medicines Company Presents Seven Hospital Data Analyses at Leading Health Economics and Outcomes Research Conferences
Apr 23, 2014: The Medicines Company Reports First Quarter 2014 Financial Results
Apr 18, 2014: Pomerantz Law Firm Announces the Filing of a Class Action Against The Medicines Company and Certain Officers
Feb 19, 2014: The Medicines Company Reports Fourth Quarter and Full Year 2013 Financial Results
Feb 12, 2014: The Medicines Company Stock Trading Halted
Jan 07, 2014: The Medicines Company to Participate in Upcoming JP Morgan Healthcare Conference
Nov 27, 2013: The Medicines Company to Participate in Upcoming Investor Conference Webcasts
Nov 05, 2013: The Medicines Company to Participate in Credit Suisse Healthcare Conference

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

The Medicines Company, Key Facts
The Medicines Company, Key Employees
The Medicines Company, Key Employee Biographies
The Medicines Company, Major Products and Services
The Medicines Company, Number of Pipeline Products by Therapy Area
The Medicines Company, Number of Pipeline Products by Development Stage
The Medicines Company, Pipeline Products By Therapy Area and Development Phase
The Medicines Company, History
The Medicines Company, Other Locations
The Medicines Company, Subsidiaries
The Medicines Company, Key Competitors
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
The Medicines Company, Recent Deals Summary

LIST OF FIGURES

The Medicines Company, Pipeline Products by Therapy Area
The Medicines Company, Pipeline Products by Development Phase
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
The Medicines Company, Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014

Ask Your Question

The Medicines Company (MDCO) - Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: